Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

ions.

About Nventa Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus, or HPV. The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit http://www.nventacorp.com.

This press release contains statements which may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include clinical development and other projections as well as statements regarding the Company's future plans, objectives, performance, operating expenses, revenues, growth, profits, operating expenses or the Company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases may identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: evaluation of the remaining cohort by the end of the second quarter; the beginning of our Phase 2 clinical program; and continued advancement of HspE7 for HPV-related diseases.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by su
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015   GenoSpace , a ... interpretation and analysis of genomic and other biomedical ... has joined the company as Vice President of ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners with ... interpret, analyze and explore complex sets of genomic, ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
(Date:7/29/2015)... -- According to a new market research report, ... (2015-2020), , published by Mordor Intelligence, the Global market is ... of 2020, with North America being ... the global market size. The Global market for Stem Cells ... the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) , ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... V&O Acquisition LLC, a subsidiary of Ramius LLC (collectively, ... to the Board of Directors of Cypress Bioscience, Inc. ... acquire all of Cypress, outstanding Common Stock in a ... conditioned upon Cypress commencing exclusive negotiations with Ramius no ...
... Wash. -- New high resolution images of electrode wires ... shows them contorting as they become charged with electricity. ... ions flow in during charging, according to a paper ... . The work suggests how rechargeable batteries eventually give ...
... biologists and signal-processing experts from Rice University, the Marine ... universities have won a $6 million grant from the ... nature,s best camouflage artists. Ultimately, the team hopes to ... colors and patterns produced by marine animals. "Our ...
Cached Biology Technology:Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 3Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 4Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 5Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 6Charging makes nano-sized electrodes swell, elongate and spiral 2Charging makes nano-sized electrodes swell, elongate and spiral 3Nano squid skin: DOD awards $6M for metamaterials research 2Nano squid skin: DOD awards $6M for metamaterials research 3
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... the growing mobile commerce market announces a revised version of one ... The commercial will air on CNBC in New York ... and San Francisco metro areas. ... focuses on Wocket,s ability to replace all the cards in your ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting ... the addition of two new team members. ... David Raviv will act as head of strategic ... to providing the most secure solutions for the enterprise market. ... 7 Technologies, a provider of security and management products, which ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... Adept at blending in with their surroundings, cuttlefish are ... and can switch between them almost instantaneously. New research ... May 2006 issue of the journal Vision Research, confirms ... based on visual cues, they do so while being ...
... systemic spread of avian influenza virus in cats infected ... by Rimmelzwaan et al., "Influenza A virus (H5N1) infection ... of virus spread within and between hosts," appears in ... and is accompanied by a commentary. , ...
... unblemished skin and slow developing gills appear to be ... group of fish whose adults thrive in icy waters ... Such adaptations are important, researchers at the University of ... least two species of notothenioids that inhabit the Ross ...
Cached Biology News:Cuttlefish masters of disguise despite colorblindness 2Avian influenza virus in mammals spreads beyond the site of infection to other organ systems 2Thin tough skin, slow-growing gills protect larval Antarctic fish 2Thin tough skin, slow-growing gills protect larval Antarctic fish 3
IMAGEQUANT 100 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Recombinant Feline IL-12/IL-23 p40 (C-Terminus), CF...
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Biology Products: